Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ANTXR2 | P58335 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.42 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17779864 | 0.96 | PTPN1 (0.46) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL13290315 | 0.96 | PTPN1 (0.46) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL17552001 | 0.94 | TSHR (0.48) | PAX8TSHRPRKCAAKT1PTK2 | |
| SCHEMBL18031017 | 0.94 | TSHR (0.44) | PAX8TSHRPRKCAAKT1PTK2 | |
| SCHEMBL14199422 | 0.92 | TSHR (0.48) | PAX8TSHRPRKCAAKT1PTK2 | |
| SCHEMBL21665520 | 0.91 | TSHR (0.44) | PAX8TSHRPRKCAAKT1PTK2 | |
| SCHEMBL14199417 | 0.89 | TSHR (0.47) | PAX8TSHRPRKCAAKT1PTK2 | |
| SCHEMBL13447782 | 0.89 | TSHR (0.55) | PAX8TSHRPTPN1USP2MEN1 | |
| SCHEMBL17850340 | 0.89 | TSHR (0.55) | PAX8TSHRPTPN1USP2MEN1 | |
| SCHEMBL17850321 | 0.89 | TSHR (0.55) | PAX8TSHRPTPN1USP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340679-A1 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-11-24 | — | — | US | disclosed |
| US-20160333342-A1 | Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes | BANK OF AMERICA, N.A. | 2016-11-17 | — | — | US | disclosed |
| US-20160298122-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MYLIP/IDOL GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160298124-A1 | COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-10-13 | — | — | US | disclosed |
| US-20160264966-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160244766-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160186172-A1 | Compositions and methods for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression | ALNYLAM PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160186180-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-06-30 | — | — | US | disclosed |
| US-9376680-B2 | Serpinc1 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160115476-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20150247143-A1 | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2015-09-03 | — | — | US | disclosed |
| US-9068184-B2 | Compositions and methods for inhibition of expression of protein C (PROC) genes | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140235693-A1 | SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140194489-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140179768-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140142162-A1 | Compositions and Methods for Inhibition of Expression of Protein C (PROC) Genes | BANK OF AMERICA, N.A. | 2014-05-22 | — | — | US | disclosed |
| US-20140113957-A1 | Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes | BANK OF AMERICA, N.A. | 2014-04-24 | — | — | US | disclosed |
| US-20130281511-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2013-10-24 | — | — | US | disclosed |
| US-20130158097-A1 | COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130123332-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MYLIP/IDOL GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340679-A1 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | GCKR, KHK, HK1 | PAX8 1928/4885TSHR 1776/4885PRKCA 288/4885 |
| US-20140194489-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE | TMPRSS6, TMPRSS2, TMPRSS11D | PAX8 2815/4885TSHR 3775/4885PRKCA 1811/4885 |
| US-20160244766-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | PAX8 2890/4885TSHR 4761/4885PRKCA 2269/4885 |
| US-20130123332-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MYLIP/IDOL GENE | MSI2, MGLL, DCLRE1B | PAX8 2123/4885TSHR 4580/4885PRKCA 1318/4885 |
| US-20130158097-A1 | COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS | COL1A1, SMAD3, COL2A1 | PAX8 2222/4885TSHR 4631/4885PRKCA 840/4885 |
| US-20160298124-A1 | COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF | CFB, CFH, HNRNPA2B1 | PAX8 1791/4885TSHR 3513/4885PRKCA 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.